September 29, 2008
 The ROI for Targeted Therapies: A Strategic Perspective
Assessing the Barriers and Incentives for Adopting
Personalized Medicine
The Deloitte Center for Health Solutions takes an in-depth look at personalized medicine's economic value proposition and the importance of ROI for multiple
stakeholders in advancing adoption of personalized medicine. Each return on investment was different according to each stakeholder: consumers, payers,
diagnostic test makers, and biotechnology or pharmaceutical firms.
| 
To download the file in PDF format, you first need to download the free Adobe Acrobat Viewer. The Acrobat Viewer will
launch the file so that you can see the document and/or print it.